OncoMatch/Clinical Trials/NCT06005493
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Is NCT06005493 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AZD5863 for gastric cancer.
Treatment: AZD5863 — This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Pancreatic Cancer
Biomarker criteria
Required: CLDN18 positive expression (positive)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced/metastatic
Must have received at least one prior line of systemic therapy in the advanced/metastatic setting
Lab requirements
Blood counts
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Kidney function
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Liver function
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Jacksonville, Florida
- Research Site · Rochester, Minnesota
- Research Site · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify